Infectious Diseases (all articles)
Retrospective Study | Clinical features and management of individuals admitted to hospital with monkeypox
13 Jan, 2023 | 13:33h | UTC
Rapid review on monkeypox policies among the G20 nations: relevance to policy and practitioner
13 Jan, 2023 | 13:34h | UTC
Study suggests delivering high concentrations of antibiotics into the implantation site is feasible for infections in implanted CV electronic devices
13 Jan, 2023 | 13:26h | UTCRegional Antibiotic Delivery for Implanted Cardiovascular Electronic Device Infections – Journal of the American College of Cardiology (link to abstract – $ for full-text)
Commentaries:
Direct Delivery of Antibiotics to CV Device Pocket Infections Appears Promising – TCTMD
Cohort Study | Antibiotic exposure linked to increased risk of inflammatory bowel disease
13 Jan, 2023 | 13:25h | UTCNews Release: Frequent use of antibiotics may heighten inflammatory bowel disease risk in over 40s – BMJ Newsroom
Commentaries:
Antibiotics may increase risk of inflammatory bowel disease, study finds – CIDRAP
Antibiotic Exposure Positively Linked to IBD Development – HealthDay
Commentary on Twitter
#GUTPressRelease on the paper by @AdamFayeMD, @KristineAllin, @manasiagrawalmd, @PREDICTIBD et al
"Antibiotic use as a risk factor for inflammatory bowel disease across the ages: a population-based cohort study" viahttps://t.co/zc9bG3CpSm#GUTInTheNews pic.twitter.com/xra8wfEgnr
— Gut Journal (@Gut_BMJ) January 9, 2023
An investigational T-cell therapy shows promise against six viral infections common after stem cell transplants
13 Jan, 2023 | 13:10h | UTC
RCT | A 24-week, all-oral regimen for rifampin-resistant tuberculosis
12 Jan, 2023 | 13:27h | UTCA 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis – New England Journal of Medicine
Commentary: Trial results show superiority of shorter, all-oral treatment for drug-resistant TB – CIDRAP
WHO consolidated guidelines on tuberculosis | Drug-resistant tuberculosis treatment, 2022 update
12 Jan, 2023 | 13:30h | UTCSee also:
– WHO consolidated guidelines on tuberculosis: module 1: prevention: tuberculosis preventive treatment
RCT | Early treatment with Molnupiravir did not reduce hospitalizations in high-risk adults with COVID-19
12 Jan, 2023 | 13:24h | UTCCommentaries:
Molnupiravir doesn’t cut Omicron hospitalization, death but can speed recovery – CIDRAP
The dangers of non-randomized, observational studies: experience from the COVID-19 epidemic
12 Jan, 2023 | 13:26h | UTC
RCT | Second-line levofloxacin-based quadruple therapy vs. bismuth-based quadruple therapy for Helicobacter pylori eradication
12 Jan, 2023 | 13:06h | UTCSecond-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial – The Lancet Gastroenterology & Hepatology (link to abstract – $ for full-text)
Commentary on Twitter
New research – Liou et al – Second-line levofloxacin-based quadruple therapy vs bismuth-based quadruple therapy for H pylori eradication and long-term changes to the gut #microbiota and antibiotic resistome: an RCThttps://t.co/Aipu3TRyFr#Hpylori #microbiome #AMR @emadelomar pic.twitter.com/aeFMAI3FCj
— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) December 20, 2022
SR | Interventions for the eradication of methicillin‐resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis
12 Jan, 2023 | 13:04h | UTC
Review | Early diagnosis and prevention of infections in cirrhosis
12 Jan, 2023 | 12:47h | UTCEarly Diagnosis and Prevention of Infections in Cirrhosis – Seminars in Liver Disease
Statement | Pre-procedure and pre-admission COVID-19 testing no longer recommended for asymptomatic patients
11 Jan, 2023 | 14:36h | UTCRecommendation Statement: Asymptomatic screening for severe acute respiratory coronavirus virus 2 (SARS-CoV-2) as an infection prevention measure in healthcare facilities: Challenges and considerations – Infection Control & Hospital Epidemiology
Commentary: Infectious disease board recommends hospitals stop screening asymptomatic patients for Covid-19 – STAT
Circulating spike protein detected in post–COVID-19 mRNA vaccine myocarditis
11 Jan, 2023 | 14:30h | UTCCirculating Spike Protein Detected in Post–COVID-19 mRNA Vaccine Myocarditis – Circulation
Commentary: Free spike proteins in the blood appear to play a role in myocarditis post-COVID mRNA vaccine – News Medical
Review | Durability of vaccine-induced and natural immunity against COVID-19
11 Jan, 2023 | 14:29h | UTC
Monkeypox (hMPXV infection): a practical review
11 Jan, 2023 | 14:25h | UTCMonkeypox (hMPXV infection): A practical review – American Journal of Medicine
WHO Interim Guidance | Surveillance, case investigation and contact tracing for mpox (monkeypox)
10 Jan, 2023 | 14:45h | UTC
MRI of acute neck infections: evidence summary and pictorial review
10 Jan, 2023 | 14:33h | UTCMRI of acute neck infections: evidence summary and pictorial review – Insights into Imaging
WHO updates recommendations on HPV vaccination schedule
9 Jan, 2023 | 14:57h | UTCNews Release: WHO updates recommendations on HPV vaccination schedule – World Health Organization
Guideline: Human papillomavirus vaccines: WHO position paper, December 2022 – World Health Organization
Commentaries:
WHO supports 1-dose HPV vaccine strategy – CIDRAP
Commentary on Twitter
🆕 WHO has revised its recommendations on possible schedules for human papillomavirus (#HPV) vaccines & now recommends:
👉1 or 2-doses for girls & women aged 9-20
👉2 doses with a 6-month interval for women 21+https://t.co/m0KZyH6sPR pic.twitter.com/W4PeS4raV9— World Health Organization (WHO) (@WHO) December 21, 2022
RCT | VV116 vs. Nirmatrelvir–Ritonavir for oral treatment of Covid-19
9 Jan, 2023 | 14:50h | UTCVV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19 – New England Journal of Medicine
Commentaries:
Study could pave way for new antiviral, as China grapples with Covid wave – STAT
Chinese oral COVID-19 drug equally effective with Paxlovid: study
VV116 Noninferior to Nirmatrelvir-Ritonavir for COVID-19 – HealthDay
Commentary on Twitter
In a Chinese trial involving participants with symptomatic mild-to-moderate Covid-19, VV116 (an oral analogue of remdesivir) was noninferior to nirmatrelvir–ritonavir with respect to the time to sustained clinical recovery.
Read the full study: https://t.co/zckTB3Rvb9 pic.twitter.com/0TVF7hEXjP
— NEJM (@NEJM) December 28, 2022
The WHO estimates of excess mortality associated with the COVID-19 pandemic
9 Jan, 2023 | 14:48h | UTCThe WHO estimates of excess mortality associated with the COVID-19 pandemic – Nature
Commentary: Pandemic’s Two-Year Global Death Toll May Be Close to 15 Million – HealthDay
RCTs | Vaccines for Zaire Ebola virus disease.
16 Dec, 2022 | 13:46h | UTCRandomized Trial of Vaccines for Zaire Ebola Virus Disease – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Ebola vaccine regimens safe, immunogenic in adults and children – NIH News Releases
Commentaries:
Ebola vaccine strategies show safety and immune response – CIDRAP
Commentary on Twitter
In two randomized trials of Ebola vaccines, safety and immune responses in adults and children were assessed for three regimens with two different vaccines. All three induced immune responses lasting at least 1 year. https://t.co/JUMN8Ieygv pic.twitter.com/NajlnA2B7y
— NEJM (@NEJM) December 14, 2022
RCT | Efficacy and safety of azithromycin vs. placebo to treat lower respiratory tract infections associated with low procalcitonin.
16 Dec, 2022 | 13:30h | UTCEfficacy and safety of azithromycin versus placebo to treat lower respiratory tract infections associated with low procalcitonin: a randomised, placebo-controlled, double-blind, non-inferiority trial – The Lancet Infectious Diseases (link to abstract – $ for full-text)
Commentary on Twitter
New research: Efficacy and safety of azithromycin versus placebo to treat lower respiratory tract infections associated with low procalcitonin: a randomised, placebo-controlled, double-blind, non-inferiority trialhttps://t.co/EZW7YdxPPU pic.twitter.com/4zlsVN5NtT
— The Lancet Infectious Diseases (@TheLancetInfDis) December 14, 2022
Review | Human papillomavirus vaccination and cervical cancer risk.
16 Dec, 2022 | 13:26h | UTCHuman papillomavirus vaccination and cervical cancer risk – The BMJ
BHIVA guidelines on antiretroviral treatment for adults living with HIV-1 2022.
15 Dec, 2022 | 13:52h | UTCBHIVA guidelines on antiretroviral treatment for adults living with HIV-1 2022 – HIV Medicine